Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... SAN DIEGO , March 27, 2015 /PRNewswire/ ... informatics company, today announced new data showing that, ... Mantis TM technology provided highly equivalent interpretations ... cause disease, and did so in a fraction ... pave the way for more comprehensive genetic analysis ...
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
(Date:3/27/2015)... According to a new market research report ... Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, ... Global Forecasts to 2019 ", published by MarketsandMarkets, the Electrophysiology ... by 2019 with a CAGR of around 10.3% during ... Browse   90   ma rket data T ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Md., Dec. 13, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... with Megapharm Ltd., one of Israel,s leading private biotech, ... of Fanapt™  in Israel. "We are excited ...
... VIEW, Calif., Dec. 13, 2011 Alexza Pharmaceuticals, Inc. ... Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food ... (Staccato® loxapine) be approved for use as a single ... recommended Risk Evaluation and Mitigation Strategy (REMS), for the ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 2FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 3FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 4FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 5
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes of ... time, key information for understanding and treating this intractable ... story on the Surviving Mesothelioma website. , ... British Columbia Cancer Agency, and PhenoPath lab in Seattle, ... and mutations that can lead to peritoneal mesothelioma ...
(Date:3/28/2015)... 2015 Healthpointe’s otolaryngologists, medical practitioners who ... disorders, are now offering a wide variety of ... is characterized by the presence of phantom sounds or ... tinnitus is a prevalent symptom that can arise due ... non-fatal, tinnitus can impede a person’s quality of life. ...
(Date:3/28/2015)... Purity Products®, a leading direct ... release of their revolutionary new weight loss product, ... double-blind, placebo-controlled clinical studies to be effective in ... MuffinStop™ is a combination of two traditionally used ... together to create one of the most innovative ...
(Date:3/27/2015)... March 27, 2015 Wellness for Cancer–the ... business criteria for the spa and wellness industry–has certified ... who have experienced or are living with cancer. ... Wellness 365® Network, will be identified with a special ... a provider of safe, therapeutic services for cancer patients. ...
(Date:3/27/2015)... First Choice Emergency Room opened its new Summerwood ... W Lake Houston Pkwy, Houston, Texas and is open 24-7. ... to delivering the highest quality emergency medical care to my ... Choice Emergency Room Summerwood. , To celebrate the ... Creek High School at First Choice Emergency Room’s ribbon cutting ...
Breaking Medicine News(10 mins):Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2
... Kate Weber, registered dietician, certified personal trainer, marathoner, and wellness enthusiast ... to live a better, longer, healthier and younger ... ... Dec. 17 be, better nutrition for active,lifestyles available exclusively at ...
... BC, Dec. 17 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... Aspreva,s,shareholders and optionholders have approved the proposed acquisition ... wholly-owned Canadian,subsidiary, at a price of US$26.00 per ... held this morning, the transaction was approved,by over ...
... U.S. hospitals , , MONDAY, Dec. 17 (HealthDay News) -- ... pain and anxiety that often follows major surgery, new ... response was equivalent to a [dose] of morphine, which ... B. Hinshaw, professor of surgery and a member of ...
... with their teeth than professionals might think, survey finds , , ... much happier with the condition of their teeth and smiles ... view eyes and teeth as the most important aspects of ... ease with the appearance of their teeth, the study found. ...
... Aim to Facilitate the Training of Interventional Cardiologists ... Treat Growing Population of Cardiovascular Patients, ... launched today by the,Society for Cardiovascular Angiography and ... fund approved training positions,thereby expanding the number of ...
... CSG/SportsCoatings,today announced a major deal that ... FabricAide(TM), to 25 high schools in,Virginia,s Fairfax ... District is the model for how schools ... towards minimizing prevalent,bacterial issues like staph and ...
Cached Medicine News:Health News:be(R) is Making Health Simple With Complimentary, Expert Online Diet, Nutrition and Exercise Advice 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 3Health News:Aspreva obtains shareholder approval for acquisition by Galenica 4Health News:Massage Eases Pain, Anxiety After Surgery 2Health News:Dentists Take Dimmer View of Patients' Smiles 2Health News:Dentists Take Dimmer View of Patients' Smiles 3Health News:Dentists Take Dimmer View of Patients' Smiles 4Health News:SCAI Announces New Program to Support Interventional Cardiology Training Fellowships 2Health News:SCAI Announces New Program to Support Interventional Cardiology Training Fellowships 3Health News:Virginia School District Gets Proactive Against MRSA 2
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: